Autoimmune Treatment Market Report 2026

The autoimmune treatment market size has grown rapidly in recent years. It will grow from $8.63 billion in 2025 to $9.84 billion in 2026 at a compound annual growth rate (CAGR) of 14%. The growth in the historic period can be attributed to improved availability of immunosuppressive drugs, expansion of rheumatology and immunology services, growing clinical experience in autoimmune care, increased patient diagnosis rates, wider access to specialty medications.

The autoimmune treatment market size is expected to see rapid growth in the next few years. It will grow to $16.53 billion in 2030 at a compound annual growth rate (CAGR) of 13.9%. The growth in the forecast period can be attributed to increasing investment in novel biologics development, rising demand for personalized autoimmune therapies, expansion of digital monitoring and follow-up care, growing focus on reducing long-term disease complications, increased research into immune system modulation. Major trends in the forecast period include increasing adoption of biologic therapies, rising use of targeted immunomodulators, growing integration of long-term disease management programs, expansion of personalized treatment regimens, enhanced focus on combination drug therapies.

The increase in healthcare spending is expected to drive the growth of the autoimmune treatment market in the coming years. Healthcare spending encompasses all costs related to providing medical services, family planning initiatives, nutrition programs, and emergency assistance with a focus on health. An increase in healthcare expenditures would facilitate the development of more advanced therapies and medical technologies for autoimmune treatment. For example, according to the economic forecast from the Office for Budget Responsibility (OBR) and Treasury, the UK's planned healthcare spending is expected to rise to £192 billion ($244.43 billion) in 2024/25, up from £182 billion ($231.7 billion) in 2022/23. Similarly, the National Health Expenditures Accounts (NHEA) from KFF, a US-based independent health policy research organization, project that healthcare spending in the United States will grow by 5% from 2023 to 2024, reaching $4.9 trillion. Thus, the increase in healthcare spending is contributing to the growth of the autoimmune treatment market.

Major companies in the autoimmune treatment market are increasingly focusing on launching innovative clinical trial platforms to secure a competitive advantage. These clinical trial platforms in autoimmune treatment utilize advanced technologies and personalized strategies to improve efficacy, safety, and patient outcomes. For example, in August 2023, the Scleroderma Research Foundation, a US-based non-profit organization, introduced the CONQUEST trial platform. The CONQUEST initiative aims to advance research and therapies for scleroderma, a rare autoimmune condition affecting connective tissues. It tackles key challenges in clinical development and facilitates progress in scleroderma therapeutics. The CONQUEST platform clinical trial is the first of its kind for rare autoimmune diseases and is designed to rapidly assess potential treatments for interstitial lung disease linked to systemic sclerosis (SSc-ILD), as well as global SSc outcomes, including those targeting skin and other disease aspects.

In August 2023, Eli Lilly and Company, a US-based pharmaceutical firm, acquired DICE Therapeutics, Inc. for $2.4 billion. The acquisition expands Lilly's immunology portfolio by integrating DICE's innovative oral therapeutic candidates, including oral IL-17 inhibitors currently in clinical development for treating chronic immunological disorders. DICE Therapeutics, Inc. is a US-based pharmaceutical company specializing in the development of novel oral therapies for autoimmune and inflammatory conditions.

Major companies operating in the autoimmune treatment market are Abbott Laboratories, Amgen Inc., Eli Lilly and Company, Pfizer Inc., F Hoffmann-La Roche AG, AstraZeneca PLC, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Biogen Idec Inc., GSK PLC, Genentech Inc., AbbVie Inc., Celgene Corporation, Gilead Sciences Inc., Merck & Co. Inc., Novartis International AG, Sanofi SA, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., UCB SA, Alexion Pharmaceuticals Inc., AnaptysBio Inc., Apellis Pharmaceuticals Inc., Arena Pharmaceuticals Inc., Aurinia Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., Cabaletta Bio Inc., ChemoCentryx Inc., Corbus Pharmaceuticals Holdings Inc., CSL Limited.

North America was the largest region in the autoimmune treatment market in 2025. The regions covered in the autoimmune treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the autoimmune treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the autoimmune treatment market by increasing costs of imported biologic drugs, specialty pharmaceuticals, diagnostic support tools, and advanced therapeutic equipment used in disease management. Healthcare providers in North America and Europe are most affected due to reliance on globally sourced biologics, while Asia-Pacific faces pricing pressure on treatment expansion. These tariffs are contributing to higher treatment costs and reimbursement challenges. However, they are also driving domestic biologics manufacturing, regional pharmaceutical innovation, and greater investment in localized drug production capabilities.

The autoimmune treatment market research report is one of a series of new reports that provides autoimmune treatment market statistics, including autoimmune treatment industry global market size, regional shares, competitors with a autoimmune treatment market share, detailed autoimmune treatment market segments, market trends and opportunities, and any further data you may need to thrive in the autoimmune treatment industry. This autoimmune treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Autoimmune treatment involves the management and care of a patient to address an autoimmune disease or disorder. This condition occurs when the immune system begins attacking the body's own cells. Autoimmune treatment is applied to manage and treat autoimmune diseases.

The primary categories of products in autoimmune treatment include consumables and assay kits, instruments, and services. Consultation involves seeking guidance from other physicians or healthcare professionals for diagnostic evaluations, therapeutic procedures, or additional services. Diagnosis is the process of determining the nature of a disease or other condition by assessing the signs and symptoms. The main service categories encompass consultation and diagnosis, therapy and monitoring, and drug development, covering various diseases such as rheumatoid arthritis, systemic lupus erythematosus, Sjögren’s syndrome, thyroiditis, scleroderma, and others. The major drug classes consist of anti-inflammatory agents, anti-hyperglycemics, NSAIDs, interferons, and others. The primary end users are clinical laboratories, hospitals, and others.

The autoimmune treatment includes revenues earned by entities by providing immunosuppressive therapy, biological treatment, immuno-suppressing medications services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.